STAT3 rs4796793 contributes to lung cancer risk and clinical outcomes of platinum-based chemotherapy
- 21 Downloads
Signal transducer and activator of transcription (STAT) 3 plays a vital role in carcinogenesis and drug response. Platinum-based chemotherapy is the first-line treatment for lung cancer patients, especially those in advanced stages. In the present study, we investigated the association of STAT3 polymorphism rs4796793 with lung cancer susceptibility, platinum-based chemotherapy response, and toxicity.
A total of 498 lung cancer patients and 213 healthy controls were enrolled in the study. 467 of them received at least 2-cycle platinum-based chemotherapy. Unconditional logistical regression analysis was used to assess the associations.
STAT3 rs4769793 G allele carriers had an increased susceptibility of lung cancer [additive model: adjusted OR (95% CI) 1.376 (1.058–1.789), P = 0.017; recessive model: adjusted OR (95% CI) 1.734 (1.007–2.985), P = 0.047]. Rs4769793 was not significantly associated with platinum-based chemotherapy response in lung cancer patients. STAT3 rs4796793 was associated with an increased risk of severe overall toxicity [additive model: adjusted OR (95% CI) 1.410 (1.076–1.850), P = 0.013; dominant model: adjusted OR (95% CI) 1.638 (1.091–2.459), P = 0.017], especially hematological toxicity [additive model: adjusted OR (95% CI) 1.352 (1.001–1.826), P = 0.049].
STAT3 rs4796793 may be considered as a potential candidate biomarker for the prediction of susceptibility and prognosis in Chinese lung cancer patients. However, well-designed studies with larger sample sizes are required to verify the results.
KeywordsSTAT3 rs4769793 Lung cancer Susceptibility Platinum-based chemotherapy Prognosis
The authors thank all the subjects who volunteered to take part in the study.
The work was supported by the National Key R&D Program of China (No. 2017YFC0909900) and Hubei Province health and family planning scientific research project (WJ2017M118).
Compliance with ethical standards
Conflict of interest
All authors have no conflict of interest to disclose.
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee, and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent was obtained from all individual participants included in the study.
- 9.Zhao L, Zhang Q, Luan X et al. (2015) STAT3 and STAT5b polymorphism contributes to breast cancer risk and clinical outcomes. Int J Clin Exp Pathol 8(2):2033–2038Google Scholar
- 14.Duffaud F, Therasse P (2000) New guidelines to evaluate the response to treatment in solid tumors. Bull Cancer 87(12):881–886Google Scholar
- 19.Zhao H, Wang Z, Wu H et al. (2015) STAT3 genetic variant, alone and in combination with STAT5b polymorphism, contributes to breast cancer risk and clinical outcomes. Med Oncol 32 (1). https://doi.org/10.1007/s12032-014-0375-z
- 23.Yamamoto K, Ioroi T, Kanaya K et al. (2016) STAT3 polymorphism rs4796793 may be a predictive factor of tumor response to multiple tyrosine kinase inhibitors in metastatic renal cell carcinoma in Japanese population. Med Oncol 33 (3):24. https://doi.org/10.1007/s12032-016-0733-0. (Northwood, London, England)CrossRefGoogle Scholar